• Founder, Chairman, CEO, and CSO of Zenitar
• Former Chief Scientist of Guangdong Zhongsheng Pharmaceutical Co., Ltd. (002317.SZ), with 20+ years of experience in innovative drug R&D
• Level 1 Professor at West China Hospital, Level 2 Professor at Sichuan University, and Deputy Director of the State Key Laboratory of Biotherapy
• Has led or participated in the development of 10+ innovative drug programs in hematology, oncology, diabetes, and pulmonary fibrosis, including 2 assets in Phase 3, 3 in Phase 2, and 4 in Phase 1
• Has led multiple major national projects for innovative drug development under China’s 11th, 12th, and 13th Five-Year Plans of the Ministry of Science and Technology
• Has published more than 430 SCI papers as corresponding author in journals such as Nature Communications, Science Advances, Clinical Cancer Research, and Journal of Medicinal Chemistry.
• Nominated “Most Highly Cited Chinese Researcher” and included in Stanford University’s global top 2% scientists list in 2020, 2022, 2023, 2024, 2025 and 2026.
• Holds more than 60 granted Chinese and international patents, including those granted in the US, Australia, and Japan.

Dr. Tomer Mark is a board-certified hematologist-oncologist and clinical development executive with more than 20 years of experience in academic medicine, clinical research, and the biopharmaceutical industry. His work has focused on developing novel therapies for hematologic malignancies, including myelofibrosis (MF), other myeloproliferative neoplasms, multiple myeloma, lymphoma, acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS). He has also worked extensively in cellular therapy and in strategies to improve T-cell fitness. Across these areas, he has led global clinical development, late-stage clinical trials, regulatory strategy, medical oversight, translational development, and investigator engagement.

• At Zenitar, Dr. Mark leads medical strategy and oversight for the Company's clinical development programs outside China, with an initial focus on flonoltinib maleate. His responsibilities include the U.S. Phase 2 program, global development planning, regulatory strategy, and engagement with investigators and other external experts.
• Prior to joining Zenitar, Dr. Mark served as Senior Vice President, Head of Hematology, Clinical Development at Karyopharm Therapeutics, after previously serving as Senior Vice President, Medical Strategy. He led medical development across a broad hematology portfolio that included myelofibrosis, multiple myeloma, lymphoma, AML, and MDS. He also built and led a T-cell fitness program focused on understanding and improving immune-cell function in patients with hematologic malignancies.
• Dr. Mark has extensive experience across Phase 1–3 clinical development, medical monitoring, benefit-risk assessment, translational strategy, and regulatory engagement. He has interacted directly with the U.S. Food and Drug Administration and the European Medicines Agency across multiple development programs.
• Before joining the biopharmaceutical industry, Dr. Mark was an Associate Professor of Medicine at the University of Colorado Anschutz Medical Campus. There, he led the Plasma Cell Disorders and Autologous Stem Cell Transplant Programs and was actively involved in cellular therapy for multiple myeloma. He previously held academic and clinical roles at Weill Cornell Medicine and NewYork-Presbyterian Hospital.
• Dr. Mark earned his MD from Stony Brook University, an MSc in Clinical Investigation from Weill Cornell Medical College, and a BS from Yale University. He completed his fellowship in hematology and medical oncology at Weill Cornell Medicine. He is certified in Hematology and Medical Oncology by the American Board of Internal Medicine.

Professor Francis (Frank) Giles is a global leader in hematologic oncology and oncology developmental therapeutics, with more than 30 years of experience in academic clinical science, clinical research and the biopharmaceutical industry. His work has focused on the development of novel agents for patients with refractory malignancies, particularly the myeloproliferative neoplasms (MPNs), and the clinical global development of novel targeted therapies. His experience covers the full spectrum of developmental therapeutics from target validation, lead compound identification and verification, first-in-human clinical studies, Phase 1,2,3 clinical protocol leadership Including global pivotal regulatory approval studies, regulatory and reimbursement approval across the world.

• He currently supports Zenitar’s global clinical development strategy, including Investigator Initiated Study activities, advancement of ex-China clinical programs, development of PI/KOL, scientific advisory, patient advocacy and industrial collaboration networks, key regulatory interactions, and critical clinical and strategic decision-making.
• He has served as a senior leadership consultant to the biotechnology industry on many novel compounds being developed for patients with malignancy including Vice President of Medical Affairs and Strategic Advisor to MorphoSys. Dr. Giles is a Fellow of the European Academy of Cancer Sciences, the Royal College of Physicians of Ireland, and the Royal College of Pathologists.
• During his tenure at MorphoSys, he supported the development of pelabresib, a BET inhibitor for patients with myelofibrosis, and tafasitamab for patients with DLBCL. He also supported the global activities related to the acquisition of MorphoSys by Novartis.
• He previously served as Deputy Director of the Robert H. Lurie Comprehensive Cancer Center, Chief of the Division of Hematology/Oncology, Director of Developmental Therapeutics, and Director of the Northwestern Medicine Developmental Therapeutics Institute at Northwestern University in Chicago. He had held clinical research and leadership roles of increasing responsibility at the University of Texas Health San Antonio the University of Texas MD Anderson Cancer Center, the University of California at Los Angeles and the University of North Carolina at Chapel Hill.
• As a principal investigator, medical lead or sponsor representative, he has led or participated in numerous first-in-human, Phase 1, Phase 2 and Phase 3 international clinical studies of small-molecule targeted therapies, epigenetic modifiers, monoclonal antibodies, immunotherapies and other novel treatments, with experience spanning early dose exploration through late-stage pivotal development. His work is reflected in his being first, lead, or co-author on over 720 peer-reviewed manuscripts focused on oncology developmental therapeutics.
• He has focused on improving the prognosis of patients with MPNs from early work on the then-emerging alpha interferons in the 1980s to the present and designed and led studies in patients with advanced refractory MF of many agents with diverse mechanisms of action including JAK inhibitors, GSK-3β inhibitors, IMIDs, anti-VEGF agents, HDAC inhibitors, and Aurora kinase inhibitors. He has made major contributions to the establishment of Bcr-Abl inhibitors as the standard of care for patients with Chronic Myeloid Leukemia and Philadelphia chromosome positive Acute Lymphoblastic Leukemia.
• He has a very established focus on international collaboration in oncology developmental therapeutics. Having both European and US training, he has extensive experience in global collaborations and is the Founder and Chairman of the International Oncology Study Group (IOSG). The IOSG’s initial peer-reviewed publications in the early 2000s focused on data generated from international therapeutic studies conducted in patients from Africa, Asia, Australia, China, and the Middle and Far East. A key focus of his work has been international mentorship in the academic and biopharmaceutical arenas with a parallel devotion to global patient advocacy activities.